Clinical Trial

A Study to Evaluate IMC-002 in Neuromyelitis Optica Spectrum Disorder (NMOSD) Patients

Name: A Study to Evaluate IMC-002 in Neuromyelitis Optica Spectrum Disorder (NMOSD) Patients — clinical trial record (NCT06557174)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1/2

View on ClinicalTrials.gov →

Record status

This record was last updated August 16, 2024 (before its estimated November 10, 2025 completion). Its status may not reflect the trial's current state.

Summary

The purpose of this study is to evaluate the efficacy and safety of IMC-002 in the treatment of NMOSD.

Trial Details

NCT Number	NCT06557174
Lead Sponsor	ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.
Conditions	Neuromyelitis Optica Spectrum Disorder (NMOSD)
Enrollment	116 participants
Start Date	2024-10-10
Primary Completion	2025-11-10 (estimated)
Study Completion	2026-07-10 (estimated)
Updated on ClinicalTrials.gov	2024-08-16